Compare Docusign Inc (DOCU) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Incyte Corporation — how do they compare? Docusign Inc trades at $57.76 (market cap $11.33B), while Incyte Corporation trades at $121.51 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 2.2× Docusign Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | INCY | |
|---|---|---|
Market Cap | $11.33B | $24.54B |
Sector | Technology | Health |
52-Week High | $85.01 | $129.93 |
52-Week Low | $41.75 | $81.61 |
Enterprise Value | $10.70B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $59.64, down 1.03% today but maintaining strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $2.8B in 2024 to $3.0B in 2025 and impressive net income margin expansion to 35.87%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.09 surpassing the $0.994 estimate. Institutional activity shows mixed signals with some funds reducing positions while others increase exposure.
DOCU presents a compelling growth story with strong profitability metrics and consistent earnings beats, though valuation remains elevated at 38.53 P/E. The stock faces near-term resistance at $60-$62 levels with overbought RSI conditions. Analyst consensus leans cautious with 67.86% hold ratings, suggesting potential consolidation before further upside. Key risks include competitive pressures in e-signature space and execution challenges in maintaining current growth trajectory.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
